Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

News Daily News

FDA Drops REMS Requirement for Antihypertensive Aprocitentan

Michael O'Riordan

April 09, 2025

News Opinion Off Script

Evoque and Patisiran: A Tale of Two Regulatory Journeys

Sanjay Kaul, MD

March 29, 2024

News Daily News

Abiomed Recalls Labeling for Left-Sided Impella Pumps: FDA

Caitlin E. Cox

March 21, 2024

News Daily News

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

Michael O'Riordan

September 15, 2023

News Daily News

Generic Dabigatran Lots Pulled for Nitrosamine Impurity

Michael O'Riordan

March 28, 2023

News Daily News

Uptick in ‘Implausible’ Cancers Reported After ARB Recalls

L.A. McKeown

August 20, 2021

News Daily News

FDA: Some Tainted Losartan Must Remain on US Market to Maintain Adequate Access for Patients

L.A. McKeown

March 21, 2019

News Daily News

FDA Provides Update on Tainted ARB Investigation, With New Impurity Found

Todd Neale

March 04, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2019

Caitlin E. Cox

January 31, 2019

News Daily News

More Blood-Pressure Drugs Recalled Due to Cancer-Causing Impurities

Shelley Wood

December 10, 2018

News Daily News

FDA: Contaminated Irbesartan Now Under Voluntary Recall

Michael O'Riordan

October 31, 2018

News Daily News

FDA Recalls Valsartan-Containing Drugs After Detection of Carcinogen

Michael O'Riordan

July 16, 2018

News Daily News

Experimental FAAH Inhibitors Do Not Pose Safety Risk, FDA Concludes

Michael O'Riordan

August 12, 2016

Advertisement

FDA Drops REMS Requirement for Antihypertensive Aprocitentan

Evoque and Patisiran: A Tale of Two Regulatory Journeys

Abiomed Recalls Labeling for Left-Sided Impella Pumps: FDA

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

Generic Dabigatran Lots Pulled for Nitrosamine Impurity

Uptick in ‘Implausible’ Cancers Reported After ARB Recalls

FDA: Some Tainted Losartan Must Remain on US Market to Maintain Adequate Access for Patients

FDA Provides Update on Tainted ARB Investigation, With New Impurity Found

TCTMD’s Top 10 Most Popular Stories for January 2019

More Blood-Pressure Drugs Recalled Due to Cancer-Causing Impurities

FDA: Contaminated Irbesartan Now Under Voluntary Recall

FDA Recalls Valsartan-Containing Drugs After Detection of Carcinogen

Experimental FAAH Inhibitors Do Not Pose Safety Risk, FDA Concludes

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content